Es sind 4+ Publikationen für dieses Produkt verfügbar. Der Kaninchen Polyklonal anti-IDO1 Antikörper wird verwendet zum Nachweis von IDO1 in Proben von Maus. Er wurde validiert für WB, ELISA, IHC und ICC.
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
Lot specific
Buffer
0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.
Konservierungsmittel
Without preservative
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Short Term Storage: +4°C Long Term Storage: -20°C Stable for at least 6 months after receipt when stored at -20°C.
Haltbarkeit
6 months
Jung, Lee, Chang, Lee, Jeong, Lee, Park, Han, Seo, Lee, Park: "Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 5, pp. 3146-54, (2009) (PubMed).
Yen, Lin, Chen, Huang, Yang, Chang, Lei, Lai: "A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, Issue 2, pp. 641-9, (2009) (PubMed).
Cook, Bickerstaff, Wang, Nadasdy, Della Pelle, Colvin, Orosz: "Spontaneous renal allograft acceptance associated with "regulatory" dendritic cells and IDO." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 180, Issue 5, pp. 3103-12, (2008) (PubMed).
Yadav, Burudi, Alirezaei, Flynn, Watry, Lanigan, Fox: "IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4." in: Glia, Vol. 55, Issue 13, pp. 1385-96, (2007) (PubMed).
Target
IDO1
(Indoleamine 2,3-Dioxygenase 1 (IDO1))
Andere Bezeichnung
IDO
Hintergrund
IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T-cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T-cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.